Small Molecule Inhibitors of PFKFB3 as Therapeutic Targets for Atherosclerosis

The pathologic foundation of atherosclerotic cardiovascular disease, which has a worldwide effect on mortality and morbidity, is atherosclerosis. The inhibition of the monocyte macrophage inflammatory reaction is crucial in the struggle with atherosclerosis as it is the main mechanism affecting atherosclerosis. All organisms must go through the identical stage of glycolysis. PFKFB3, a bifunctional enzyme, relates to the PFKFB series of isoenzymes who regulate glycolysis. It impacts the level of fructose 2,6-bisphosphate (fru2,6-BP) in the cytoplasm. There are, however, a variety of issues associated with the study into 3PO's role in atherosclerosis. Additional confirmation of 3PO that requires being described in the development of atherosclerosis. Be able to indicate any prospective pharmaceutical effects.